Healthcare
Live Price
Offline$7.72
-1.09% today
Window Change
-2.13%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ImmunityBio, Inc. (IBRX) is a Healthcare stock with a market cap of $7.30B and listed on NASDAQ. The stock last traded around $7.71 and down 2.1% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +668.3%, EPS growth of +35.6%, a dividend yield of 0.0%. What stands out right now is revenue +668.3%, EPS +35.6%, free cash flow +22.4% with operating margin -226.0% and ROIC -56.9%. Valuation already assumes a fairly strong business story at price/sales 64.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IBRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IBRX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IBRX Max Drawdown
-10.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for IBRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$934.0K
+289.2% YoY
FY Net Income
-$346.8M
+16.8% YoY
Free Cash Flow
-$308.0M
+25.9% YoY
Revenue Growth
+668.3%
EPS Growth
+35.6%
Gross Margin
92.4%
Net Margin
-310.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 113M | 15M | 622K | 240K | 934K |
| Gross Profit | 113M | 15M | 622K | 240K | 934K |
| Operating Income | -256M | -344M | -362M | -351M | -330M |
| EBITDA | -224M | -264M | -479M | -352M | -321M |
| Net Income | -351M | -414M | -583M | -417M | -347M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88M | 143M | 265M | 105M | 181M |
| Total Assets | 502M | 383M | 504M | 362M | 469M |
| Total Liabilities | 1.0B | 871M | 1.1B | 812M | 713M |
| Shareholder Equity | -500M | -489M | -587M | -447M | -242M |
| Total Debt | 878M | 504M | 727M | 724M | 646M |
| Net Debt | 790M | 361M | 461M | 619M | 465M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
274M
+18.7% YoY
Capital Expenditures
34M
+57.1% YoY
Free Cash Flow
308M
+25.9% YoY
Key ratios
Gross Margin
92.4%
Operating Margin
-226.0%
Net Margin
-310.2%
ROE
64.3%
Debt / Equity
-1.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.